The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback